These results suggest a possible mechanism whereby Fgf16 probably prevents angiotensin II-induced cardiac hypertrophy and fibrosis by competing with Fgf2 for the binding site for Fgfr1c. The gene discussed is AGT; the disease is cardiac hypertrophy.